SuperworthelectroCore ECOR
- Market cap
- $63.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $37M
- +33% on a year ago
- Net margin
- −40.0%
- Free cash flow yield
- −15.3%
electroCore trades at 1.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $37M over the last twelve months, up 33% on a year earlier with a −40% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.5M+128% | $5.2M+103% | $5.4M+96% | $6.1M+73% | $6.6M+45% | $7M+36% | $6.7M+23% | $7.4M+20% | $8.7M+33% | $9.2M+31% | $9.6M+43% | $9.4M+28% | |
| Cost of revenue | $661K+156% | $1.1M+72% | $888K+94% | $838K+43% | $1.1M+61% | $994K−10% | $1M+14% | $939K+12% | $1.2M+15% | $1.1M+8% | $1.2M+20% | $1.3M+36% |
| Gross profit | $3.8M+124% | $4.1M+113% | $4.6M+96% | $5.3M+79% | $5.5M+43% | $6.1M+48% | $5.7M+25% | $6.4M+22% | $7.5M+36% | $8.2M+35% | $8.4M+47% | $8.2M+27% |
| R&D | $1.2M−23% | $1.1M−32% | $399K−78% | $635K−45% | $521K−58% | $805K−27% | $642K+61% | $511K−20% | $662K+27% | $920K+14% | $740K+15% | $818K+60% |
| SG&A | $6.7M+19% | $6.9M+12% | $8M+19% | $7.3M+7% | $7.6M+13% | $8.3M+20% | $8.9M+11% | $9.4M+30% | $9.7M+27% | $10.2M+23% | $12.9M+46% | $10.1M+7% |
| −$4.1M−26% | −$4M−33% | −$3.8M−38% | −$2.6M−48% | −$2.7M−36% | −$3.1M−22% | −$3.8M−1% | −$3.5M+35% | −$2.9M+9% | −$2.9M−4% | −$5.3M+39% | −$2.8M−21% | |
| Interest expense | n/a | n/a | $4.2K+106% | $4.3K+91% | $5K | $261K | $5K+19% | $4.5K+5% | $208K+4060% | $324K+24% | $318K+6260% | $321K+7033% |
| Pre-tax income | −$4M−26% | −$4M−31% | −$3.6M−40% | −$2.7M−46% | −$2.5M−38% | −$3.2M−20% | −$3.9M+8% | −$3.7M+38% | −$3.4M+36% | −$3M−7% | −$5.6M+43% | −$3.1M−17% |
| $0 | $25K+79% | −$122K−42% | $0 | $0 | $29K+16% | −$48K−61% | $0 | $0 | $51K+76% | −$321K+569% | $0 | |
| Net income | −$4M−26% | −$4M−30% | −$3.5M−40% | −$2.7M−46% | −$2.5M−38% | −$3.2M−20% | −$3.9M+10% | −$3.7M+38% | −$3.4M+36% | −$3M−6% | −$5.3M+37% | −$3.1M−17% |
| −$0.68−43% | −$0.61−51% | −$0.53−57% | −$0.38−63% | −$0.31−54% | −$0.40−34% | −$0.47−11% | −$0.44+16% | −$0.40+29% | −$0.34−15% | −$0.59+26% | −$0.33−25% | |
| 5.9M+31% | 6.6M+41% | 6.6M+40% | 7M+48% | 8.1M+36% | 8.2M+24% | 8.3M+25% | 8.3M+18% | 8.4M+4% | 8.9M+9% | 9M+8% | 9.4M+13% |
Cost of revenue: Q1 FY17: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY17: 6 months less the 3 months printed beside them.
R&D: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY17: 6 months less the 3 months printed beside them.
Net income: Q1 FY17: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest electroCore's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ECORelectroCore | $63.6M | n/m | n/a | 1.7× | +33% | −40.0% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on electroCore
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .